DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

14.87 0.02 (0.13%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

FOLD $14.87 0.13%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.71
Previous Close $14.85
Daily Range $14.56 - $15.17
52-Week Range $5.13 - $18.83
Market Cap $1.8B
P/E Ratio -14.85
Dividend (Yield) $0.00 (0.0%)
Volume 914,566
Average Daily Volume 1,833,026
Current FY EPS -$1.19




Drug Makers

Amicus Therapeutics, Inc. (FOLD) Description

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. Website:

News & Commentary Rss Feed

Why Amicus Therapeutics Skyrocketed 21% in July

A new therapy for Fabry disease could become available next year.

First Week of FOLD August 21st Options Trading

'Mad Money' Lightning Round: Forget El Pollo Loco, Buy Chipotle

5 Biotechs Leerink Analysts Are Watching

Amicus Therapeutics' (FOLD) CEO John Crowley on Q2 2015 Results - Earnings Call Transcript

Amicus Therapeutics (FOLD) Q2 2015 Results - Earnings Call Webcast

3 Tiny Stocks to Buy If Biotech Tumbles

Ophthotech Corp., Portola Pharmaceuticals, and Amicus Therapeutics could be buys if biotech stocks fall.

Can The Uptrend Continue for Amicus Therapeutics (FOLD)? - Tale of the Tape

5 Drugs That Investors May Be Undervaluing

One Foolish investor thinks these five drugs could send shares in these companies higher.

Why Shares in Amicus Therapeutics Shot Higher in June

Amicus Therapeutics shares jumped on news that it had filed for European approval of Galafold, a therapy for Fabry disease.

See More FOLD News...

FOLD's Top Competitors

FOLD $14.87 (0.13%)
Current stock: FOLD
AMGN $155.89 (0.11%)
Current stock: AMGN
GILD $107.78 (-0.19%)
Current stock: GILD
BIIB $303.69 (-0.26%)
Current stock: BIIB